|
|
Post by darbara on Nov 27, 2015 12:33:27 GMT
Daclatasvir launching December 1st week In India, followed by Generic Harvoni
|
|
jolie
New Member
Posts: 23 
|
Post by jolie on Nov 27, 2015 17:38:32 GMT
hi darbara, nice to meet you,
do you have more info on this, like a link perhaps ? thanks,
jolie xxxx
|
|
|
|
Post by darbara on Nov 27, 2015 22:24:18 GMT
No I dont HAVE a link but my Doc informed me and 2 other people who are involved. It will be the news next week and as soon as I see a public post I will post it here This news will be posted here when the page is updated: www.cdsco.nic.in/forms/default.aspx |
|
|
|
Post by darbara on Nov 28, 2015 18:52:28 GMT
Just to add Greg has also seen the document to confirm the release so before christmas it should be on sale
|
|
|
|
Post by Admin on Nov 29, 2015 4:20:43 GMT
|
|
|
|
Post by darbara on Nov 29, 2015 7:03:50 GMT
Fantastic, now hope sales begin soon
|
|
|
|
Post by darbara on Dec 8, 2015 17:47:51 GMT
HYDERABAD, DEC 8:
Generic pharmaceuticals and anti retroviral drug manufacturer Hetero has received approval for the fixed dose combination drug Ledipasvir sofosbuvir from the Drug Controller General of India (DCGI).
The drug, Ledisof, is a generic version of Gilead Sciences’ brand Harvoni which is approved by the US FDA.
The Hyderabad based Hetero had singed a non-exclusive licensing agreement with Gilead in September last year to manufacture and market the drug indicated for the treatment of chronic hepatitis C and is the first company to receive DCGI approval for this category of drug.
``We are happy to extend the fixed dose combination therapy Ledipasvir sofosbuvir (Ledisof) to Indian patients which is much more effective than Sofosbuvir,’’ B P S Reddy, Chairman and Managing Director of Hetero said in a release issued here on Monday.
Hepatitis C is a growing health concern in many developing countries including India which is estimated to have about 12 to 18 million people infected with hepatitis C.
(This article was published on December 8, 2015)
|
|
